PT Jayamas Medica Industri Tbk

NEW
ISX:OMED (Indonesia)   Ordinary Shares
Rp 157 (0%) Mar 27
14.76
P/B:
1.81
Market Cap:
Rp 4.25T ($ 254.13M)
Enterprise V:
Rp 3.22T ($ 192.62M)
Volume:
146.40K
Avg Vol (2M):
2.35M
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
146.40K
Avg Vol (2M):
2.35M

Business Description

Description
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing medical devices and other household health supplies. It initially began with the manufacture of urine bags, OneMed later expanded in the manufacturing business of medical equipment and supplies in Indonesia with a range of variants of products manufactured locally. The Company and its Subsidiaries have three segments: Manufacturing; Distribution and Retail.
Name Current Vs Industry Vs History
Cash-To-Debt 6.89
Equity-to-Asset 0.86
Debt-to-Equity 0.08
Debt-to-EBITDA 0.44
Interest Coverage 17.16
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 9.83
Distress
Grey
Safe
Beneish M-Score -2.63
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 39.25
9-Day RSI 35.84
14-Day RSI 34.53
3-1 Month Momentum % -8.89
6-1 Month Momentum % -7.34
12-1 Month Momentum % -16.75

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 7.22
Quick Ratio 5.13
Cash Ratio 4.04
Days Inventory 181.54
Days Sales Outstanding 49.65
Days Payable 25.4

Dividend & Buy Back

Name Current Vs Industry Vs History
Dividend Yield % 1.83
Dividend Payout Ratio 0.27
Forward Dividend Yield % 1.83
5-Year Yield-on-Cost % 1.83
Shareholder Yield % 2.19

Financials

ISX:OMED's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

PT Jayamas Medica Industri Tbk Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil Rp) 1,835,014.619
EPS (TTM) (Rp) 10.64
Beta -
3-Year Sharpe Ratio -
3-Year Sortino Ratio -
Volatility % 11.79
14-Day RSI 34.53
14-Day ATR (Rp) 4.951767
20-Day SMA (Rp) 162.55
12-1 Month Momentum % -16.75
52-Week Range (Rp) 143 - 212
Shares Outstanding (Mil) 27,058.85

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

PT Jayamas Medica Industri Tbk Filings

Filing Date Document Date Form
No Filing Data

PT Jayamas Medica Industri Tbk Stock Events

Financials Calendars
Event Date Price (Rp)
No Event Data

PT Jayamas Medica Industri Tbk Frequently Asked Questions

What is PT Jayamas Medica Industri Tbk(ISX:OMED)'s stock price today?
The current price of ISX:OMED is Rp157.00. The 52 week high of ISX:OMED is Rp212.00 and 52 week low is Rp143.00.
When is next earnings date of PT Jayamas Medica Industri Tbk(ISX:OMED)?
The next earnings date of PT Jayamas Medica Industri Tbk(ISX:OMED) is .
Does PT Jayamas Medica Industri Tbk(ISX:OMED) pay dividends? If so, how much?
The  Dividend Yield %  of PT Jayamas Medica Industri Tbk(ISX:OMED) is 1.83% (As of Today), Highest Dividend Payout Ratio of PT Jayamas Medica Industri Tbk(ISX:OMED) was 0.33. The lowest was 0.27. And the median was 0.33. The  Forward Dividend Yield % of PT Jayamas Medica Industri Tbk(ISX:OMED) is 1.83%. For more information regarding to dividend, please check our Dividend Page.

Press Release

Subject Date
No Press Release